Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sight Sciences, Inc. - Common Stock (NQ:SGHT)

3.080 +0.050 (+1.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sight Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
Sight Sciences' Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use
Sight Sciences Inc (NASDAQ: SGHT) published two-year results of the so-called "Romeo" study of the OMNI Surgical System. 
Via Benzinga
Recap: Sight Sciences Q1 Earnings
Via Benzinga
A Preview Of Sight Sciences's Earnings
Via Benzinga
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical
From Sight Sciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract... 
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Clinical data includes long-term trial results and robust real-world comparative data from IRIS® Registry 
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023
The event will include presentations from leading glaucoma surgeons and remarks from the Sight Sciences executive management team 
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures 
From Sight Sciences, Inc.
Via GlobeNewswire
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.  
Via Benzinga
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
From Sight Sciences, Inc.
Via GlobeNewswire
3 Prime Healthcare Takeover Targets
These three companies are attractive targets for their potential. 
Via The Motley Fool
Lions Gate Entertainment, DexCom, Yelp And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Sight Sciences Announces 1,000th TearCare® Customer Installation
Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) 
From Sight Sciences, Inc.
Via GlobeNewswire
Super Micro Computer, Rayonier Advanced Materials And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Dow Jones gaining around 30 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
Company Also Announces CFO Transition 
From Sight Sciences, Inc.
Via GlobeNewswire
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). 
Via Benzinga
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
From Sight Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.